Empowered Funds LLC bought a new position in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 326,197 shares of the biotechnology company's stock, valued at approximately $7,408,000. Empowered Funds LLC owned approximately 0.45% of Innoviva as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in INVA. Parallel Advisors LLC boosted its position in shares of Innoviva by 82.8% during the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 534 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Innoviva in the 2nd quarter worth approximately $30,000. Allworth Financial LP purchased a new position in Innoviva in the 2nd quarter worth approximately $42,000. EverSource Wealth Advisors LLC increased its holdings in shares of Innoviva by 297.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company's stock worth $48,000 after buying an additional 1,795 shares during the last quarter. Finally, Danske Bank A S bought a new position in shares of Innoviva in the 3rd quarter worth $55,000. 99.12% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
INVA has been the topic of several research reports. Zacks Research cut shares of Innoviva from a "hold" rating to a "strong sell" rating in a research report on Friday, July 31st. Wall Street Zen lowered shares of Innoviva from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. BTIG Research reissued a "buy" rating and issued a $42.00 target price on shares of Innoviva in a research note on Monday, June 22nd. Weiss Ratings lowered Innoviva from a "buy (b)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Finally, Cantor Fitzgerald cut their price objective on Innoviva from $36.00 to $34.00 and set an "overweight" rating for the company in a report on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Innoviva has a consensus rating of "Hold" and an average price target of $34.75.
Read Our Latest Stock Report on INVA
Innoviva Stock Performance
Innoviva stock opened at $20.97 on Monday. The company has a current ratio of 16.01, a quick ratio of 15.18 and a debt-to-equity ratio of 0.21. The firm has a 50-day moving average of $21.66 and a 200-day moving average of $22.37. The firm has a market cap of $1.52 billion, a P/E ratio of 5.11 and a beta of 0.35. Innoviva, Inc. has a 1-year low of $16.52 and a 1-year high of $25.15.
Innoviva Profile
(
Free Report)
Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva's portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.
The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Innoviva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.
While Innoviva currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
